Oxaliplatin plus S-1

DRUG3 trials

Sponsors

Peking University Cancer Hospital & Institute, Huazhong University of Science and Technology, Ruijin Hospital

Conditions

Adjuvant ChemotherapyDocetaxelGastric CancerGastric Cancer (GC)OxaliplatinStage 3 Cancer

Phase 3

Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer

TerminatedNCT02867839

Peking University Cancer Hospital & InstituteGastric Cancer

Start: 2017-04-24End: 2021-09-01Updated: 2024-12-03

Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

Huazhong University of Science and TechnologyGastric Cancer

Start: 2019-03-08End: 2023-03-31Target: 294Updated: 2022-01-04

Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer

RecruitingNCT07366528

Ruijin HospitalAdjuvant Chemotherapy, Docetaxel, Gastric Cancer (GC) +2

Start: 2025-12-15End: 2030-10-31Target: 387Updated: 2026-01-26

Related Papers

Adjuvant oxaliplatin plus S-1 versus docetaxel plus S-1 for stage III gastric cancer after D2 gastrectomy (DRAGON-Adjuvant): A multicenter, open-label, phase 3, randomized, non-inferiority study.

Journal of Clinical Oncology2026-05-28

A multicenter randomized phase III study of albumin-bound paclitaxel combined with S-1 (AS) versus oxaliplatin combined with S-1 (SOX) for first-line treatment of advanced gastric cancer (GAPSO study).

Journal of Clinical Oncology2022-01-192 citations

Nab-paclitaxel plus S-1 <i>versus</i> oxaliplatin plus S-1 as first-line treatment in advanced gastric cancer: results of a multicenter, randomized, phase III trial (GAPSO study)

Therapeutic Advances in Medical Oncology2022-01-0114 citations

Postoperative chemotherapy with S-1 plus oxaliplatin versus S-1 alone in locally advanced gastric cancer (RESCUE-GC study): a protocol for a phase III randomized controlled trial

Chinese Journal of Cancer Research2017-01-0110 citations